Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 6:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 133 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Anti-coagulation therapy Clear all
Completed Phase 4 Interventional

Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy

NCT02227550
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Vitamin K antagonist, Apixaban
Drug
Lead sponsor
Atrial Fibrillation Network
Other
Eligibility
18 Years and older
Enrollment
676 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
New York, New York • Philadelphia, Pennsylvania • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 1, 2026, 6:12 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)

NCT00786474
View directory record Official record
Conditions
Arterial Thromboembolic Events, Atrial Fibrillation
Interventions
Placebo, Dalteparin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
1,884 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Oct 1, 2026, 6:12 PM EDT
Recruiting Not applicable Interventional

Anti-Reflux Endoscopic TX Using APC (AREA) in GERD Patients: (The AREA Study)

NCT05570448
View directory record Official record
Conditions
Gastro Esophageal Reflux
Interventions
ARAT, Sham intervention (control)
Procedure
Lead sponsor
Midwest Veterans' Biomedical Research Foundation
Other
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 1, 2026, 6:12 PM EDT
Recruiting Early Phase 1 Interventional

Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation

NCT06615596
View directory record Official record
Conditions
Atrial Fibrillation (AF)
Interventions
discontinue anticoagulation therapy, Anticoagulant drugs, Catheter Ablation
Behavioral · Drug · Procedure
Lead sponsor
China National Center for Cardiovascular Diseases
Government
Eligibility
18 Years and older
Enrollment
3,160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 1, 2026, 6:12 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin

NCT00927862
View directory record Official record
Conditions
Thromboembolism
Interventions
IWPC adapted genotype-guided dosing algorithm for warfarin, Modified IWPC genetic-guided warfarin dosing algorithm, Standard of care treatment
Genetic · Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
2,415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 25, 2012 · Synced Oct 1, 2026, 6:12 PM EDT
Terminated Not applicable Interventional Results available

Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation

NCT02928497
View directory record Official record
Conditions
Stroke
Interventions
WATCHMAN LAAC Device Implant, Single Antiplatelet Therapy or No Therapy (Control)
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
71
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 1, 2026, 6:12 PM EDT
Completed Phase 4 Interventional

Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia

NCT00002386
View directory record Official record
Conditions
HIV Infections, Hemophilia A
Interventions
Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 1, 2026, 6:12 PM EDT
Recruiting Phase 3 Interventional

A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

NCT05611801
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
marstacimab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
1 Year to 17 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 1, 2026, 6:12 PM EDT
Completed Phase 4 Interventional Results available

Covid-19 Associated Coagulopathy

NCT04360824
View directory record Official record
Conditions
COVID 19 Associated Coagulopathy
Interventions
Intermediate dose thromboprophylaxis, Standard of Care thromboprophylaxis
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 100 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Iowa City, Iowa • La Crosse, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 1, 2026, 6:12 PM EDT
Completed Phase 4 Interventional Results available

Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI

NCT04483583
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor 60mg, Clopidogrel
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 1, 2026, 6:12 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

NCT04077463
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Lazertinib, Amivantamab, Carboplatin, Pemetrexed
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
18
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 1, 2026, 6:12 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Relationship Between Osteoporosis and Chronic Oral Anticoagulation Therapy With Warfarin

NCT00665613
View directory record Official record
Conditions
Osteoporosis
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 1, 2026, 6:12 PM EDT
Completed Phase 1 Interventional

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

NCT01176474
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
NY-ESO-1 157-165 (165V), Nivolumab, gp100:280-288 (288V), Montanide ISA 51 vegetable grade (VG), Ipilimumab, Apheresis Procedure
Biological · Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
16 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 1, 2026, 6:12 PM EDT
Recruiting Phase 4 Interventional

International Care Bundle Evaluation in Cerebral Hemorrhage Research

NCT06429332
View directory record Official record
Conditions
Intracerebral Hemorrhage, Intracerebral Haemorrhage, Intraventricular Hemorrhage, Stroke, Cerebrovascular Disease
Interventions
Reversal of Oral anticoagulation within 30 minutes, Early intensive blood pressure lowering, Treatment of pyrexia, Hyperglycemia treatment, Do-not-resuscitate (DNR) or withdrawal of care, Referral to Intensive Care, Referral to Neurosurgery, Repeat brain imaging, Standard care
Other · Diagnostic Test
Lead sponsor
Region Skane
Other
Eligibility
18 Years and older
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 1, 2026, 6:12 PM EDT
Completed Not applicable Interventional Results available

Study to Develop a Reliable Nomogram That Incorporates Clinical and Genetic Information

NCT00401414
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis, Atrial Fibrillation
Interventions
Warfarin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 30, 2013 · Synced Oct 1, 2026, 6:12 PM EDT
Completed No phase listed Observational

Biomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving Chemotherapy

NCT01132833
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Neoplasm, Thromboembolism
Interventions
enzyme-linked immunosorbent assay, laboratory biomarker analysis, medical chart review
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 22, 2016 · Synced Oct 1, 2026, 6:12 PM EDT
Terminated Not applicable Interventional Results available

Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury

NCT01400893
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
SCD
Device
Lead sponsor
SeaStar Medical
Industry
Eligibility
18 Years to 80 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 1, 2026, 6:12 PM EDT
Not listed No phase listed Observational

Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia

NCT03288441
View directory record Official record
Conditions
Hematologic Neoplasms, Thrombocytopenia, Anticoagulants, Platelet Aggregation Inhibitors
Interventions
Hold, Prophylactic dose antithrombotic, Change antithrombotic Drug, Change platelet transfusion threshold, Full dose antithrombotics, Mechanical measures, Intermediate dose antithrombotic
Drug · Biological · Device
Lead sponsor
Maastricht University Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 1, 2026, 6:12 PM EDT
Not listed Not applicable Interventional

Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)

NCT01213914
View directory record Official record
Conditions
Burns, Hemofiltration, Kidney Failure, Acute, Shock, Septic
Interventions
An FDA approved continuous renal replacement device, Control Group
Device · Other
Lead sponsor
American Burn Association
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
9
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 1, 2026, 6:12 PM EDT
Completed Not applicable Interventional Results available

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

NCT02744092
View directory record Official record
Conditions
Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Blood Clot
Interventions
Rivaroxaban, Apixaban, Edoxaban, Dabigatran, Warfarin, Dalteparin, Enoxaparin, Fondaparinux
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
811 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
151
States / cities
Chula Vista, California • Fremont, California • Fresno, California + 104 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 1, 2026, 6:12 PM EDT
Completed Not applicable Interventional

Electronic Alerts for Stroke Prevention in Patients With Atrial Fibrillation or Atrial Flutter

NCT02339493
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
Computer Electronic Alert
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 1, 2026, 6:12 PM EDT
Completed Not applicable Interventional Results available

Safety Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Renal Failure

NCT01072682
View directory record Official record
Conditions
Acute Renal Failure
Interventions
Selective cytopheretic device (SCD)
Device
Lead sponsor
SeaStar Medical
Industry
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
7
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 1, 2026, 6:12 PM EDT
Recruiting Not applicable Interventional

DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis

NCT05701917
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
Interventions
ClotTriever System, Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.
Device · Drug
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
48
States / cities
Scottsdale, Arizona • Tucson, Arizona • Orange, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 1, 2026, 6:12 PM EDT
Terminated Phase 1 Interventional

Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding

NCT01561950
View directory record Official record
Conditions
Haemostasis, Healthy
Interventions
eptacog alfa (activated), clopidogrel, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 1, 2026, 6:12 PM EDT